Application in Gene Editing in Ovarian Cancer Therapy

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells

“…Site-specific gene editing technology presents a promising avenue for ovarian cancer (OC) treatment, offering the potential to combat drug resistance and enhance patient outcomes [ 18 ]. These innovative approaches encompass gene-specific knockouts and the regulation of gene expression [ 18 ].…”

“…Site-specific gene editing technology presents a promising avenue for ovarian cancer (OC) treatment, offering the potential to combat drug resistance and enhance patient outcomes [ 18 ]. These innovative approaches encompass gene-specific knockouts and the regulation of gene expression [ 18 ]. Notably, several studies have shown the potential of these approaches: CRISPR-Cas9-mediated knockdown of ABCB1 reversed doxorubicin resistance in OC cells [ 19 ], BRCA1 knockout synergistically suppressed poly(ADP-ribose) polymerase (PARP)-1 expression in a mouse OC cell line (ID8), increasing sensitivity to cisplatin and PARP inhibitors [ 20 , 21 ].…”

“…However, the lack of safe and effective delivery systems and off-target effects limit the further application of gene editing technologies [ 23 ]. CRISPR-dCas9-based epigenetic editing may serve as an alternative approach to apply to sensitize chemotherapy for OC [ 18 ]. Epigenetic editing offers a safer method for OC treatment, as it possesses three advantages not typically found in traditional gene editing: 1) independence from DNA repair pathways, high efficiency, and minimal side effects; 2) reversibility, in contrast to the essentially irreversible nature of gene editing; and 3) risk of off-target effects compared to traditional gene editing [ 24 ].…”